Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03063515 · ClinicalTrials.gov registry record · Phase 1
AchE Inhibitor and Insulin
A Phase 1 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03063515 is a Phase 1 study that has completed, run by University of Miami. The registered enrollment target is 12 participants.
The verdict
NCT03063515, a Phase 1 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The investigator will examine the effect of a single dose of pyridostigmine, AchE inhibitor on insulin secretion in healthy subjects. Each subject will undergo an intravenous glucose tolerance test (IVGTT) where IV glucose will be administered and the glucose excursion and insulin secretion response will be evaluated by measuring insulin and glucose at different time points. The test will be carried out twice, once without and once with the administration of a single dose of Pyridostigmine on two separate days. The investigator hypothesizes that inhibiting AChE will potentiate insulin secretion.
Interventions
- DRUG Pyridostigmine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-04-19 |
| Est. Completion | 2018-12-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03063515
The ClinicalTrials.gov registry entry for NCT03063515 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pyridostigmine is the first listed.
NCT03063515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03063515 about?
NCT03063515 is a clinical study titled "AchE Inhibitor and Insulin". The investigator will examine the effect of a single dose of pyridostigmine, AchE inhibitor on insulin secretion in healthy subjects. Each subject will undergo an intravenous glucose tolerance test (IVGTT) where IV glucose will be administered and the glucose excursion and insulin secretion response...
What is the current status of trial NCT03063515?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-04-19. Estimated completion is 2018-12-14.
What interventions are being tested in trial NCT03063515?
The interventions under investigation include: Pyridostigmine (DRUG).
Who is sponsoring clinical trial NCT03063515?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.